Given the association between Cav3.2 and trastuzumab-resistance in HER2-positive breast cancer cell lines in vitro and increased expression within the luminal subtype, we explored the potential of Cav3.2 as a biomarker in predicting patient survival and/or outcomes with chemotherapy. This evidence concerns the gene CACNA1H and breast carcinoma.